Pyxis Oncology, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $256.9M
- Price
- $3.08
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.28%
- Volume
- 682.3K
About
Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors. Additionally, PYX-102 is an immune-therapeutic currently under investigation for the treatment of solid tumors. The company's portfolio also features a range of investigational antibody-drug conjugate (ADC) candidates: PYX-201, a novel ADC being developed for NSCLC, breast cancer, and other solid tumors; PYX-202, another novel ADC aimed at small cell lung cancer (SCLC), soft tissue sarcoma, and other solid tumors; and PYX-203, an ADC undergoing evaluation for acute myeloid leukemia and myeloid dysplastic syndrome. Pyxis Oncology was founded in 2018 and is based in Cambridge, Massachusetts.
Quick stats
Shares outstanding83.4M
Computed float36.4M
Float / shares43.6%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001782223
AI Summary
AI-generated1/8
standardbullishearnings
Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones
Pyxis Oncology reported a second quarter net loss of $25.3 million, or $0.40 per share, with zero revenue compared to $2.8 million in the prior year, but strengthened its balance sheet by closing a private placement that delivered $50 million in upfront gross proceeds.
The financing extends the company’s cash runway into the second quarter of 2027, providing sufficient capital to fund operations through upcoming clinical milestones for its lead asset MICVO.
Management remains on track to report updated monotherapy data from the Phase 1 study in second-line head and neck cancer this fall, followed by updated combination data with Merck’s KEYTRUDA in the fourth quarter of 2026.
Red flags
- General and administrative expenses increased 83% year-over-year to $9.9 million due to severance costs and stock-based compensation
- Q2 revenue dropped to $0 from $2.8 million in the prior year